Trial reportEuropean journal of heart failure2014
Rationale and study design of the NEuroCardiac TherApy foR Heart Failure Study: NECTAR-HF.
Trial report in European journal of heart failure, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01385176 (Neural Cardiac Therapy for Heart Failure Study), which is not on this map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neural Cardiac Therapy for Heart Failure Study
Who cites it
39 citing papers in PubMed, 63 citations in OpenAlex.
- Effects of Low-Level Tragus Stimulation on Endothelial Function in Heart Failure With Reduced Ejection Fraction.Journal of cardiac failure · 2021Trial
- Timing Considerations for Noninvasive Vagal Nerve Stimulation in Clinical Studies.AMIA ... Annual Symposium proceedings. AMIA Symposium · 2019Trial
- Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial.European heart journal · 2015Trial
- Quantifying acute physiological biomarkers of transcutaneous cervical vagal nerve stimulation in the context of psychological stress.Brain stimulationTrial
- Bursting Parameters Alter Excitatory Postsynaptic Currents in Nucleus Tractus Solitarius Neurons: Implications for Clinical Vagus Nerve Stimulation.Journal of neurochemistry · 2026Article
- Time course of early and delayed myocardial protection induced by vagal nerve stimulation preconditioning.Basic research in cardiology · 2026Article
- Cell-free strategies for cardiomyocyte proliferation and heart repair.Pharmacological reports : PR · 2026Review
- Neurocardiology: translational advancements and potential.The Journal of physiology · 2025Review
- Clinical neurocardiology: defining the value of neuroscience-based cardiovascular therapeutics - 2024 update.The Journal of physiology · 2025Review
- Electroceuticals: Unlocking the promise of therapies.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2024Review
- U-shaped association between serum calcium and in-hospital mortality in patients with congestive heart failure.ESC heart failure · 2024Observational
- The vagus nerve in cardiovascular physiology and pathophysiology: From evolutionary insights to clinical medicine.Seminars in cell & developmental biology · 2024Review
- VNS improves VSMC metabolism and arteriogenesis in infarcted hearts through m/n-AChR-Akt-SDF-1α in adult male rats.Journal of molecular histology · 2024Article
- Measuring and modeling the effects of vagus nerve stimulation on heart rate and laryngeal muscles.Bioelectronic medicine · 2023Article
- Clinical perspectives on vagus nerve stimulation: present and future.Clinical science (London, England : 1979) · 2022Review
- Advances in Our Clinical Understanding of Autonomic Regulation Therapy Using Vagal Nerve Stimulation in Patients Living With Heart Failure.Frontiers in physiology · 2022Review
- Closed-Loop Vagus Nerve Stimulation for the Treatment of Cardiovascular Diseases: State of the Art and Future Directions.Frontiers in cardiovascular medicine · 2022Review
- Direct measurement of vagal tone in rats does not show correlation to HRV.Scientific reports · 2021Article
- Anodal block permits directional vagus nerve stimulation.Scientific reports · 2020Article
- Activation of Oxytocin Neurons Improves Cardiac Function in a Pressure-Overload Model of Heart Failure.JACC. Basic to translational science · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 10 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsIncreased sympathetic activation and reduced parasympathetic tone are important pathophysiological contributors to the progression of heart failure, and are associated with poor outcome in patients. The aim of this study is to determine if vagal nerve stimulation (VNS) is a promising approach to modulate autonomic function and slow cardiac remodelling and the progression of heart failure.
methodsThe NECTAR-HF (NEural Cardiac TherApy foR Heart Failure) trial is designed to evaluate whether the Boston Scientific VNS device is safe and may attenuate cardiac remodelling, improve cardiac function and increase exercise capacity, in symptomatic heart failure patients (New York Heart Association Class II-III) with left ventricular systolic dysfunction (ejection fraction ≤35%) and receiving optimal medical therapy. Patients will be randomized in a 2:1 ratio to receive standard optimal medical treatment plus VNS system in an active mode vs. optimal medical treatment plus VNS system in an inactive mode, for a 6 month period. After the 6 month control period, inactive VNS systems will be activated and all patients will receive VNS. The study is powered to detect differences in the primary efficacy endpoint of change in left ventricular end systolic diameter. Secondary endpoints include ejection fraction, left ventricular volumes, quality of life scores, functional capacity, and changes in biomarkers.
conclusionThis Phase II, randomized clinical trial conducted with vagal stimulation for heart failure will provide important new information on the potential of this novel and promising technique.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.